Sponsors (3)
The bill funds a focused study that could produce important, disaggregated evidence and prompt stronger product-safety requirements, but it delays immediate action, may raise regulatory costs and consumer prices, and requires careful data-privacy protections.
Women of color (and other exposed women) would gain stronger, disaggregated scientific evidence about links between chemical hair straighteners and uterine cancer, helping inform prevention, diagnosis, and treatment decisions.
Results could prompt the FDA to require additional manufacturer testing and safety measures, improving product safety for consumers nationwide.
Provides Congress with a timely, evidence-based report (within two years) to guide policymaking and potential regulatory action.
Study timelines (two years for the report) may delay regulatory or consumer protections, leaving currently exposed women at potential risk in the near term.
If the study leads to new FDA testing mandates, manufacturers—especially small businesses—could face higher compliance costs that may be passed on to consumers as higher prices.
Collecting and disaggregating race/ethnicity and product-use data raises privacy and data-protection concerns for study participants if safeguards are inadequate.
Based on analysis of 2 sections of legislative text.
Directs HHS (with FDA and NIH) to study whether chemical hair straighteners are linked to uterine cancer, disaggregate results by product features and race, and assess FDA testing needs.
Official title: Direct the Secretary of Health and Human Services to study and report on the relationship between hair straighteners and uterine cancer, particularly among women of color.
Introduced July 15, 2025 by Lisa Blunt Rochester · Last progress July 15, 2025
Directs the Department of Health and Human Services, working with the FDA and NIH, to conduct a focused study on the relationship between chemical hair straightening products and uterine cancer, with special attention to higher incidence among women of color. The bill requires HHS to submit a study methodology to two congressional committees within 45 days, begin the study within 180 days, and deliver a final report within two years that disaggregates results by product characteristics and considers whether FDA should require additional testing of manufacturers.